small molecule glp 1 agonist Potential oral small-molecule GLP-1R agonist. | DDDT A potent novel small molecule
Description
56% after 13 hr, n=62
Keywords: hyperglycemia, GIP, twincretin, pathophysiology, therapeutics 1
Another oral, non-peptide GLP-1 RA (lotiglipron) has also been withdrawn from development as in early phase clinical trials resulted in elevated liver enzymes which could indicate liver toxicity [30]
The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus
However, other types of cancer occurred at a similar level between patients who took sitagliptin and those with other therapies (90)
